Clinical Trials

Find a Clinical Trial

Enrolling Trials

1-10  of  144
►
10323, Cancer Moonshot Biobank Research Protocol
Onitilo, Adedayo A
Miscellaneous Neoplasm
Adult
To support current and future investigations into drug resistance and sensitivity and other NCI-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment
Hurley, Alexa A
(715) 393-1019
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI  54868
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
Stevens Point Center
,   
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
►
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Assess the Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of BI 764198 Administered Orally Once Daily for 12 Weeks in Patients With Focal Segmental Glomerulosclerosis
Kattamanchi, Siddhartha
Nephrology
Adult
This study is open to adults with a type of kidney disease called primary focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study. Participants are put into 4 groups randomly, which means by chance. Three of the groups receive different doses of BI 764198 and one group receives placebo. Participants are in the study for about 4 months. For about 3 months, they take BI 764198 or placebo as capsules once a day. Placebo capsules look like BI 764198 capsules but do not contain any medicine. Participants visit the study site about 10 times. You can participate in this study from your home. In this case a research nurse will visit you for the study visits. Kidney health is assessed based on the analysis of urine samples, which participants collect at home. At the end of the study, the results are compared between the different groups. During the study, the doctors also regularly check the general health of the participants.
Florence, Hope
(715) 221-7255
Kauffman, Lisa D
(715) 389-5738
Mundt, Pamela S
(715) 387-5544
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Multi-center, Randomized, Double-blind, Placebo- controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Kattamanchi, Siddhartha
Nephrology
Adult
This trial is a multicenter, randomized, double-blind, placebo controlled parallel group study. The purpose of the study is to evaluate the efficacy and safety of LNP023 compared to placebo on proteinuria reduction and slowing disease progression in primary IgAN patients.
Kauffman, Lisa D
(715) 389-5738
Mundt, Pamela S
(715) 387-5544
►
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Lehman, Elmer G
Ovaries, Uterus, Cervix - Ovaries
Adult
To compare the non inferiority of bilateral salpingectomy (BLS) with delayed oophorectomy to bilateral salpingo oophorectomy (BSO) to reduce the risk of ovarian cancer among women with deleterious BRCA1 germline mutations
Adam, Iddrisu
(715) 389-4041
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor
Mosley, Anthony D
Neurology
Adult
Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating, and patients also experience associated social embarrassment. This study will assess how safe and effective BOTOX is in treating UL ET. Adverse events and change in disease activity will be evaluated. BOTOX is an investigational drug being developed for the treatment of UL ET. Participants are randomly assigned to 1 of the 4 groups, called treatment arms. Each group receives different treatment. There is 1 in 2 chance that participants will be assigned to placebo. Around 174 participants, aged 18 to 80 years with UL ET will be enrolled in approximately 40 sites in North America. Participants will receive BOTOX or placebo injections in Cycle 1 and Cycle 2. In Cycle 3, participants will receive unilateral or bilateral BOTOX injections. Each cycle is 12 weeks.
Kauffman, Lisa D
(715) 389-5738
Mundt, Pamela S
(715) 387-5544
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Manalang, Michelle
Brain, Spinal Cord
Brain, Spinal Cord - Brain Primary
Child, Adult
This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment.
Welter, Stacy L
(715) 221-6492
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Manalang, Michelle
Neuroblastoma
Child, Adult
This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Welter, Stacy L
(715) 221-6492
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation
Velasco, Jacqueline
Nephrology
Adult
The purpose of this study is to compare the QW and QD formulations of setmelanotide in patients with biallelic PPL (POMC [pro-opiomelanocortin], PCSK1 [proprotein convertase subtilisin/kexin Type 1], LEPR [leptin receptor]), heterozygous PPL, and patients with BBS. QW dosing is expected to provide a more convenient dosing regimen for these patients and would be more suitable for younger patients than QD dosing.
Leigh, Maricia
(715) 221-7275
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients With POMC, PCSK1, LEPR, SRC1, SH2B1, or PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway
Meilahn, Jill R
Nephrology
Adult, Child
The protocol describes a randomized, double-blind, placebo-controlled trial with 5 independent sub-studies of setmelanotide in patients with obesity and at least one of 6 specific gene defects in the Melanocortin-4 Receptor pathway: POMC or PCSK1 (Sub-study 035a); LEPR (Sub-study 035b); SRC1 (Sub-study 035c); SH2B1 (Sub-study 035d); PCSK1 N221D (Sub-study 035e). These 5 sub-studies have high degree of similarities. The objectives and endpoints are identical for all 5 sub-studies.
Freeman, Sandra K
(715) 387-9059
Gault, Tammy
(715) 387-5673
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449
►
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])
Trinh, Thu-Thao T
Neurology - Other
Child
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric subjects with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Florence, Hope
(715) 221-7255
Johnson, Megan A
(715) 389-4878
Leigh, Maricia
(715) 221-7275
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI  54449